# Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

> **NCT00540644** · PHASE2 · COMPLETED · sponsor: **Attaya Suvannasankha** · enrollment: 70 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** lenalidomide (Revlimid®)
- **DRUG:** Cyclophosphamide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00540644
- **Lead sponsor:** Attaya Suvannasankha
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2012-12
- **Final completion:** 2014-08
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2016-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540644, "Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00540644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*